인간 마이크로바이옴 시장 : 2029년까지의 세계 예측

출판 : MarketsandMarkets(마켓츠앤드마켓츠)출판년월 : 2022년04월

인간 마이크로바이옴 시장 : 제품(프리바이오틱스, 프로바이오틱스, 식품, 진단 테스트, 의약품), 용도(치료, 진단), 질병(감염성, 대사/내분비), 연구 기술(게노믹스, 프로테오믹스, 메타볼로믹스) – 2029년까지의 세계 예측

Human Microbiome Market by Product (Prebiotics, Probiotics, Food, Diagnostic Tests, Drugs), Application (Therapeutic, Diagnostic), Disease (Infectious, Metabolic/Endocrine), Research Technology (Genomics, Proteomics, Metabolomics) – Global Forecast to 2029

페이지수 182
도표수 210
구성 영문조사보고서
가격

리포트목차    주문/문의    납기/라이센스안내

Sample Request

The human microbiome market is projected to reach USD 1,370 million by 2029 from USD 269 million in 2023, at a CAGR of 31.1% from 2023 to 2029. The major factor driving the growth of the human microbiome market is the increasing focus on human microbiome therapy development. The human microbiome as a validated target for drug development & development of human microbiome-based tests for early disease detection and diagnosis are also factors expected to support market growth.
인간 마이크로바이옴 시장은 2023년부터 2029년까지 31.1%의 CAGR로 2023년 2억 6900만 달러에서 2029년 13억 7000만 달러에 이를 것으로 예상됩니다. 인간 마이크로바이옴 시장의 성장을 이끄는 주요 요인은 인간 마이크로바이옴 치료에 대한 관심 증가입니다 개발. 약물 개발을 위한 검증된 표적으로서의 인간 미생물군집 및 조기 질병 감지 및 진단을 위한 인간 미생물군유전체 기반 테스트의 개발 또한 시장 성장을 지원할 것으로 예상되는 요소입니다.
However, a lack of expertise and inadequate research on the human microbiome are factors expected to restrain this market’s growth.


“By product segment, the drugs segment accounted for the largest share of human microbiome market:”

Based on product, the human microbiome market is segmented into probiotics, prebiotics, diagnostic tests, drugs, and other products. Drugs segment accounted for the largest product segment in the human microbiome market. The large share of this segment can be attributed to the increasing number of human microbiome-based drug products in clinical trials and rising funding to develop microbiome-based drugs

“By application, the diagnostics segment is expected to grow at the highest CAGR during the forecast period.”
Based on application, the human microbiome market is segmented into therapeutics and diagnostics. The diagnostics segment is expected to grow at the highest CAGR during the forecast period. Advances in life science research on a wide number of diseases, technological innovations in human genome mapping, the emergence of omics technologies, and the increasing emphasis on improving the cost-effectiveness of healthcare and patient outcomes are some of the major factors driving the growth of this segment.
“By genomic technologies, the sequencing segment is expected to grow at the highest CAGR during the forecast period.”
Based on technology, the human microbiome market is further segmented into sequencing and other genomic technologies {PCR, microarray, and fluorescent in situ hybridization (FISH)}. The availability of advanced, efficient, and accurate next-generation sequencing systems at a low cost, along with the reduced cost of sequencing, has greatly boosted the adoption of the latest sequencing technologies in the human microbiome market
“North America: The largest region in the human microbiome market.”
In the human microbiome market, North America is estimated to maintain its vanguard during the forecast period. Factors such as the increasing incidence of lifestyle diseases, rising awareness on preventive healthcare, availability of funding for microbiome research, and growing acceptance of probiotic products are the factors driving the North American human microbiome market.
Breakdown of primaries

The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:

By Designation: Managers: 55%, Executives: 25%, and CXOs: 20%,
By Region: North America: 50%, Europe: 20%, APAC: 20%, and RoW: 10%
Prominent players in the human microbiome market include ENTEROME Bioscience (France), Seres Therapeutics. (US), 4D pharma (UK), OptiBiotix Health (UK), Synlogic (US), International flavors & Fragrances (US), Second Genome (US), Vedanta Biosciences (US), Ferring Pharmaceuticals (Switzerland), Evelo Biosciences (US), ViThera Pharmaceuticals (US), BiomX (Israel), Kaleido (US), YSOPIA Bioscience (France), FlightPath (US), Finch Therapeutics (US), Quantbiome (DBA Thyrve, Inc.) (US), Viome, Inc. (US), DayTwo (US), BIOHM (US), Atlas Biomed (UK), Bione (India), Luxia Scientific (France), Sun Genomics (US), and Metabiomics (US).


Research Coverage:
The report segments the human microbiome market based on region (Asia Pacific, Europe, North America, and RoW), product (prebiotics, probiotics, drugs, diagnostic tests, and other products), technology (Genomics, Proteomics, and Metabolomics), application (therapeutics and diagnostics), disease (hospitals & clinics, research centers and academic & government institutes, pharmaceutical & biotechnology companies, and other end users). The report also provides a comprehensive review of market drivers, opportunities, restraints, and challenges in the human microbiome market.
.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants in this market and provide information on the closest approximations of the revenue numbers for the overall human microbiome market and its subsegments. This report will help the stakeholders to understand the competitive landscape, to gain more insights to better position their businesses, and to plan suitable go-to-market strategies. The report will also help the stakeholders to understand the pulse of the market and provide information on key market drivers, restraints, opportunities, and challenges.


목차

TABLE OF CONTENTS

1 INTRODUCTION (Page No. – 26)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 MARKETS COVERED FOR HUMAN MICROBIOME RESEARCH SPENDING MARKET
1.3.3 YEARS COVERED FOR THE STUDY (HUMAN MICROBIOME RESEARCH SPENDING MARKET)
1.3.4 YEARS COVERED FOR THE STUDY (HUMAN MICROBIOME MARKET)
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. – 32)
2.1.1 SECONDARY DATA
2.1.2 PRIMARY SOURCES
FIGURE 1 BREAKDOWN OF PRIMARIES: HUMAN MICROBIOME MARKET
2.2 MARKET DATA ESTIMATION AND TRIANGULATION
FIGURE 2 DATA TRIANGULATION METHODOLOGY
2.2.1 MARKET ESTIMATION METHODOLOGY
FIGURE 3 MARKET SIZE ESTIMATION APPROACH: R&D SPENDING ANALYSIS-BASED ESTIMATION (FOR HUMAN MICROBIOME RESEARCH SPENDING MARKET)
FIGURE 4 HUMAN MICROBIOME RESEARCH SPENDING MARKET SIZE (USD MILLION): FINAL MARKET SIZE
2.2.2 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
FIGURE 5 FINAL CAGR PROJECTIONS (2023−2029)
2.2.3 POTENTIAL MARKET SIZE CALCULATION FOR HUMAN MICROBIOME MARKET
FIGURE 6 HUMAN MICROBIOME MARKET SIZE BASED ON EPIDEMIOLOGY APPROACH
2.3 INSIGHTS FROM PRIMARIES
FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
2.4 RESEARCH ASSUMPTIONS

3 EXECUTIVE SUMMARY (Page No. – 39)
    FIGURE 8 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023 VS. 2029 (USD MILLION)
FIGURE 9 HUMAN MICROBIOME MARKET SHARE, BY APPLICATION, 2029
FIGURE 10 HUMAN MICROBIOME MARKET, BY DISEASE, 2024 VS. 2029 (USD MILLION)
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF HUMAN MICROBIOME MARKET

4 PREMIUM INSIGHTS (Page No. – 42)
4.1 HUMAN MICROBIOME: MARKET OVERVIEW
FIGURE 12 INCREASING FOCUS ON HUMAN MICROBIOME THERAPEUTICS DEVELOPMENT TO DRIVE MARKET GROWTH
4.2 HUMAN MICROBIOME MARKET, BY TYPE (2023 VS. 2029)
FIGURE 13 FMT TO DOMINATE HUMAN MICROBIOME MARKET IN 2023
4.3 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT & APPLICATION (2023)
4.4 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY COUNTRY (2023–2029)
FIGURE 14 CHINA TO GROW AT THE HIGHEST CAGR DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. – 45)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 15 HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 MARKET DRIVERS
5.2.1.1 Rising industry-academia collaborations for microbiome research
5.2.1.2 Increasing focus on human microbiome therapeutics development
5.2.1.3 Human microbiome as a validated target for drug development
5.2.1.4 Development of human microbiome-based tests for early disease detection & diagnosis
5.2.2 MARKET RESTRAINTS
5.2.2.1 Barriers in proving the causal link between dysbiosis and diseases
5.2.2.2 Negative clinical data will adversely impact public perception of microbiomes
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 Increasing collaborations between public-private organizations
5.2.4 MARKET CHALLENGES
5.2.4.1 Government regulations
5.2.4.2 Lack of expertise and inadequate research
5.3 IMPACT OF THE COVID-19 PANDEMIC ON THE HUMAN MICROBIOME MARKET
5.4 REGULATORY ANALYSIS
5.4.1 REGULATORY LANDSCAPE FOR HUMAN MICROBIOME-BASED DRUGS
5.4.2 REGULATORY LANDSCAPE FOR HUMAN MICROBIOME-BASED FOODS
5.5 PATENT ANALYSIS

6 HUMAN MICROBIOME MARKET, BY APPLICATION (Page No. – 56)
6.1 INTRODUCTION
TABLE 1 HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
6.2 THERAPEUTIC APPLICATIONS
6.2.1 AVAILABILITY OF FUNDING FOR MICROBIOME-BASED THERAPEUTIC PRODUCTS DEVELOPMENT TO DRIVE MARKET GROWTH
TABLE 2 HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY REGION, 2023–2029 (USD MILLION)
TABLE 3 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY 2023–2029 (USD MILLION)
TABLE 4 EUROPE: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY 2023–2029 (USD MILLION)
TABLE 5 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY 2023–2029 (USD MILLION)
6.3 DIAGNOSTIC APPLICATIONS
6.3.1 INCREASING FOCUS ON BIOMARKER-BASED DIAGNOSTIC TESTS TO DRIVE MARKET GROWTH
TABLE 6 HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY REGION, 2023–2029 (USD MILLION)
TABLE 7 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY 2023–2029 (USD MILLION)
TABLE 8 EUROPE: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY 2023–2029 (USD MILLION)
TABLE 9 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY 2023–2029 (USD MILLION)

7 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY (Page No. – 62)
7.1 INTRODUCTION
TABLE 10 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
7.2 GENOMICS
TABLE 11 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY TYPE, 2021–2029 (USD MILLION)
TABLE 12 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY REGION, 2021–2029 (USD MILLION)
TABLE 13 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 14 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 15 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 2021–2029 (USD MILLION)
7.2.1 SEQUENCING
TABLE 16 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY REGION, 2021–2029 (USD MILLION)
TABLE 17 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 18 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 19 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 20 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY METHOD, 2021–2029 (USD MILLION)
7.2.1.1 16S rRNA Sequencing Method
7.2.1.1.1 Cost-effectiveness to propel identification of bacterial strains
TABLE 21 16S RRNA SEQUENCING METHOD, BY REGION, 2021–2029 (USD MILLION)
TABLE 22 NORTH AMERICA: 16S RRNA SEQUENCING METHOD, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 23 EUROPE: 16S RRNA SEQUENCING METHOD, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 24 ASIA PACIFIC: 16S RRNA SEQUENCING METHOD, BY COUNTRY, 2021–2029 (USD MILLION)
7.2.1.2 Whole-Genome Sequencing (WGS)Method
7.2.1.2.1 WGS to generate accurate reference genomes for microbial identification
TABLE 25 WGS METHOD, BY REGION, 2021–2029 (USD MILLION)
TABLE 26 NORTH AMERICA: WGS METHOD, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 27 EUROPE: WGS METHOD, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 28 ASIA PACIFIC: WGS METHOD, BY COUNTRY, 2021–2029 (USD MILLION)
7.2.1.3 Other Sequencing Methods
TABLE 29 OTHER SEQUENCING METHODS, BY REGION, 2021–2029 (USD MILLION)
TABLE 30 NORTH AMERICA: OTHER SEQUENCING METHODS, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 31 EUROPE: OTHER SEQUENCING METHODS, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 32 ASIA PACIFIC: OTHER SEQUENCING METHODS BY COUNTRY, 2021–2029 (USD MILLION)
7.2.2 OTHER GENOMIC TECHNOLOGIES
TABLE 33 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY REGION, 2021–2029 (USD MILLION)
TABLE 34 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 35 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 36 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION)
7.3 PROTEOMICS
7.3.1 TECHNOLOGICAL ADVANCEMENTS IN PROTEOMIC TECHNOLOGIES TO DRIVE MARKET GROWTH
TABLE 37 PROTEOMICS, BY REGION, 2021–2029 (USD MILLION)
TABLE 38 NORTH AMERICA: PROTEOMICS, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 39 EUROPE: PROTEOMICS, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 40 ASIA PACIFIC: PROTEOMICS, BY COUNTRY, 2021–2029 (USD MILLION)
7.4 METABOLOMICS
7.4.1 ADVANTAGES OF METABOLOMICS OVER GENOMICS AND PROTEOMICS TO DRIVE MARKET GROWTH
TABLE 41 METABOLOMICS, BY REGION, 2021–2029 (USD MILLION)
TABLE 42 NORTH AMERICA: METABOLOMICS, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 43 EUROPE: METABOLOMICS, BY COUNTRY, 2021–2029 (USD MILLION)
TABLE 44 ASIA PACIFIC: METABOLOMICS, BY COUNTRY, 2021–2029 (USD MILLION)

8 HUMAN MICROBIOME MARKET, BY TYPE (Page No. – 76)
8.1 INTRODUCTION
TABLE 45 HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION)
8.2 MICROBIOME CONSORTIA TRANSPLANTATION (FMT)
8.2.1 ADVANCEMENTS IN CLINICAL TRIALS FOR C. DIFFICILE INFECTION TREATMENT TO AUGMENT SEGMENTAL GROWTH
TABLE 46 HUMAN MICROBIOME MARKET FOR MICROBIOME CONSORTIA TRANSPLANTATION (FMT), BY REGION, 2023–2029 (USD MILLION)
TABLE 47 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR MICROBIOME CONSORTIA TRANSPLANTATION (FMT), BY COUNTRY 2023–2029 (USD MILLION)
TABLE 48 EUROPE: HUMAN MICROBIOME MARKET FOR MICROBIOME CONSORTIA TRANSPLANTATION (FMT), BY COUNTRY 2023–2029 (USD MILLION)
TABLE 49 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR MICROBIOME CONSORTIA TRANSPLANTATION (FMT), BY COUNTRY 2023–2029 (USD MILLION)
8.3 PEPTIDE
8.3.1 POTENTIAL OF PEPTIDES IN REDUCING NEURODEGENERATIVE DISORDERS TO GROW IN FORECAST PERIOD
TABLE 50 HUMAN MICROBIOME MARKET FOR PEPTIDE, BY REGION, 2023–2029 (USD MILLION)
TABLE 51 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PEPTIDE, BY COUNTRY 2023–2029 (USD MILLION)
TABLE 52 EUROPE: HUMAN MICROBIOME MARKET FOR PEPTIDE, BY COUNTRY 2023–2029 (USD MILLION)
TABLE 53 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PEPTIDE, BY COUNTRY 2023–2029 (USD MILLION)
8.4 LIVE BIOTHERAPEUTIC PRODUCT
8.4.1 GROWING R&D INVESTMENTS FOR LIVE BIOTHERAPEUTIC PRODUCTS TO BOOST SEGMENTAL GROWTH
TABLE 54 HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCT, BY REGION, 2023–2029 (USD MILLION)
TABLE 55 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCT, BY COUNTRY 2023–2029 (USD MILLION)
TABLE 56 EUROPE: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCT, BY COUNTRY 2023–2029 (USD MILLION)
TABLE 57 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCT, BY COUNTRY 2023–2029 (USD MILLION)

8.5 OTHERS
8.5.1 INCREASING FOCUS ON SMALL MOLECULES TO PROPEL SEGMENTAL GROWTH
TABLE 58 HUMAN MICROBIOME MARKET FOR OTHERS, BY REGION, 2023–2029 (USD MILLION)
TABLE 59 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHERS, BY COUNTRY 2023–2029 (USD MILLION)
TABLE 60 EUROPE: HUMAN MICROBIOME MARKET FOR OTHERS, BY COUNTRY 2023–2029 (USD MILLION)
TABLE 61 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHERS, BY COUNTRY 2023–2029 (USD MILLION)

9 HUMAN MICROBIOME MARKET, BY PRODUCT (Page No. – 85)
9.1 INTRODUCTION
TABLE 62 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
9.2 DRUGS
9.2.1 INCREASING NUMBER OF MICROBIOME-BASED DRUGS IN PIPELINE TO DRIVE SEGMENT GROWTH
TABLE 63 HUMAN MICROBIOME MARKET FOR DRUGS, BY REGION, 2023–2029 (USD MILLION)
TABLE 64 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION)
TABLE 65 EUROPE: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION)
TABLE 66 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION)
9.3 DIAGNOSTIC TESTS
9.3.1 GROWING CONSUMER AWARENESS ABOUT MICROBIOME- BASED TESTS TO DRIVE SEGMENT GROWTH
TABLE 67 HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY REGION, 2023–2029 (USD MILLION)
TABLE 68 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION)
TABLE 69 EUROPE: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION)
TABLE 70 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION)
9.4 PROBIOTICS
9.4.1 ONGOING RESEARCH PROMOTING CREDIBILITY REGARDING HEALTH CLAIMS AND SAFETY OF PROBIOTICS
TABLE 71 HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY REGION, 2023–2029 (USD MILLION)
TABLE 72 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)
TABLE 73 EUROPE: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)
TABLE 74 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)
9.5 PREBIOTICS
9.5.1 DEVELOPMENT OF TARGETED PREBIOTICS IN ENHANCING GUT MICROBIOTA TO DRIVE SEGMENT GROWTH
TABLE 75 HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY REGION, 2023–2029 (USD MILLION)
TABLE 76 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)
TABLE 77 EUROPE: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)
TABLE 78 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)
9.6 OTHER PRODUCTS
TABLE 79 HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2029 (USD MILLION)
TABLE 80 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)
TABLE 81 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)
TABLE 82 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)

10 HUMAN MICROBIOME MARKET, BY DISEASE (Page No. – 96)
10.1 INTRODUCTION
TABLE 83 HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION)
10.2 INFECTIOUS DISEASES
10.2.1 INCREASING NUMBER OF CLINICAL STUDIES FOR CLOSTRIDIUM DIFFICILE INFECTION TO DRIVE SEGMENT GROWTH
TABLE 84 DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS FOR INFECTIOUS DISEASES
TABLE 85 HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2029 (USD MILLION)
TABLE 86 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
TABLE 87 EUROPE: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
TABLE 88 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
10.3 GASTROINTESTINAL DISEASES
10.3.1 INCREASING NUMBER OF CLINICAL STUDIES FOR GASTROINTESTINAL DISEASES TO DRIVE SEGMENT GROWTH
TABLE 89 HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023–2029 (USD MILLION)
TABLE 90 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
TABLE 91 EUROPE: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
TABLE 92 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
10.4 ENDOCRINE & METABOLIC DISORDERS
10.4.1 DEVELOPMENT OF MICROBIOME MODULATORS FOR TREATMENT OF METABOLIC DISORDERS TO DRIVE SEGMENT GROWTH
TABLE 93 DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR METABOLIC DISEASES
TABLE 94 HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2029 (USD MILLION)
TABLE 95 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION)
TABLE 96 EUROPE: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION)
TABLE 97 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION)
10.5 CANCER
10.5.1 MICROBIOME-BASED PRODUCTS HAVE DEMONSTRATED EFFICACY IN TREATMENT OF PELVIC AND COLON CANCER
TABLE 98 HUMAN MICROBIOME MARKET FOR CANCER, BY REGION, 2023–2029 (USD MILLION)
TABLE 99 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION)
TABLE 100 EUROPE: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION)
TABLE 101 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION)
10.6 OTHER DISEASES
TABLE 102 HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023–2029 (USD MILLION)
TABLE 103 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
TABLE 104 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
TABLE 105 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)

11 HUMAN MICROBIOME MARKET, BY REGION (Page No. – 107)
11.1 INTRODUCTION
TABLE 106 HUMAN MICROBIOME MARKET, BY REGION, 2023–2029 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 16 NORTH AMERICA: HUMAN MICROBIOME MARKET SNAPSHOT
TABLE 107 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
TABLE 108 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 109 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
TABLE 110 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2029 (USD MILLION)
11.2.1 US
11.2.1.1 Increasing investments by NIH in support of microbiome research to drive market growth
TABLE 111 US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
TABLE 112 US: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 113 US: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Increasing government support and funds to support market growth
TABLE 114 INDICATIVE LIST OF PROJECTS ON HUMAN MICROBIOME IN 2018
TABLE 115 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
TABLE 116 CANADA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 117 CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
11.3 EUROPE
FIGURE 17 EUROPE: HUMAN MICROBIOME MARKET SNAPSHOT
TABLE 118 EU MICROBIOME PROJECT
TABLE 119 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
TABLE 120 EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 121 EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
TABLE 122 EUROPE: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2029 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Extended applications of microbiome research to therapeutic areas to boost adoption of microbiome-based products
TABLE 123 GERMANY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
TABLE 124 GERMANY: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 125 GERMANY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
11.3.2 UK
11.3.2.1 Increasing focus on microbiome-based products development to drive market growth
TABLE 126 UK: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
TABLE 127 UK: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 128 UK: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Increasing funding to boost microbiome-based products development
TABLE 129 FRANCE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
TABLE 130 FRANCE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 131 FRANCE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
11.3.4 ROE
TABLE 132 ROE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
TABLE 133 ROE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 134 ROE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 18 ASIA PACIFIC: HUMAN MICROBIOME MARKET SNAPSHOT
TABLE 135 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
TABLE 136 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 137 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
TABLE 138 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2029 (USD MILLION)
11.4.1 CHINA
11.4.1.1 Large number of human microbiome research studies to drive market growth
TABLE 139 INDICATIVE LIST OF HUMAN MICROBIOME RESEARCH STUDIES CONDUCTED IN CHINA
TABLE 140 CHINA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
TABLE 141 CHINA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 142 CHINA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 Increasing focus on funding for microbiome-based products to drive market growth
TABLE 143 JAPAN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
TABLE 144 JAPAN: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 145 JAPAN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Government funding to drive microbiome-based products development
TABLE 146 INDIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
TABLE 147 INDIA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 148 INDIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
11.4.4 REST OF ASIA PACIFIC
TABLE 149 ROAPAC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
TABLE 150 ROAPAC: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 151 ROAPAC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)
11.5 REST OF THE WORLD (ROW)
TABLE 152 ROW: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
TABLE 153 ROW: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
TABLE 154 ROW: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. – 133)
12.1 OVERVIEW
12.2 PRODUCT TYPE FOOTPRINT OF COMPANIES
TABLE 155 PRODUCT TYPE PORTFOLIO ANALYSIS: HUMAN MICROBIOME MARKET (2021)
12.3 CLINICAL PHASE FOOTPRINT OF COMPANIES
TABLE 156 CLINICAL PHASE FOOTPRINT OF COMPANIES: HUMAN MICROBIOME MARKET (2021)
12.4 DISEASE FOOTPRINT OF COMPANIES
TABLE 157 DISEASE FOOTPRINT OF COMPANIES: HUMAN MICROBIOME MARKET (2021)
12.5 COMPETITIVE SCENARIO
TABLE 158 HUMAN MICROBIOME MARKET: KEY DEALS, JANUARY 2020–JANUARY 2021

13 COMPANY PROFILES (Page No. – 137)
13.1 MAJOR PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 ENTEROME
TABLE 159 ENTEROME: BUSINESS OVERVIEW
13.1.2 SERES THERAPEUTICS
TABLE 160 SERES THERAPEUTICS: BUSINESS OVERVIEW
FIGURE 19 SERES THERAPEUTICS: COMPANY SNAPSHOT (2021)
13.1.3 4D PHARMA PLC
TABLE 161 4D PHARMA PLC: BUSINESS OVERVIEW
FIGURE 20 4D PHARMA PLC: COMPANY SNAPSHOT (2020)
13.1.4 INTERNATIONAL FLAVORS & FRAGRANCES INC.
TABLE 162 INTERNATIONAL FLAVORS & FRAGRANCES INC.: BUSINESS OVERVIEW
FIGURE 21 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY SNAPSHOT (2021)
13.1.5 OPTIBIOTIX HEALTH PLC.
TABLE 163 OPTIBIOTIX HEALTH PLC.: BUSINESS OVERVIEW
FIGURE 22 OPTIBIOTIX HEALTH PLC.: COMPANY SNAPSHOT (2020)
TABLE 164 PRODUCT LAUNCHES
13.1.6 SYNLOGIC, INC.
TABLE 165 SYNLOGIC: BUSINESS OVERVIEW
FIGURE 23 SYNLOGIC, INC.: COMPANY SNAPSHOT (2020)
13.1.7 SECOND GENOME INC.
TABLE 166 SECOND GENOME INC.: BUSINESS OVERVIEW
13.1.8 VEDANTA BIOSCIENCES, INC.
TABLE 167 VEDANTA BIOSCIENCES, INC.: BUSINESS OVERVIEW
13.1.9 FERRING PHARMACEUTICALS
TABLE 168 FERRING PHARMACEUTICALS: BUSINESS OVERVIEW
13.1.10 EVELO BIOSCIENCES, INC.
TABLE 169 EVELO BIOSCIENCES: BUSINESS OVERVIEW
FIGURE 24 EVEL0 BIOSCIENCES, INC.: COMPANY SNAPSHOT (2020)
13.1.11 BIOMX
TABLE 170 BIOMX: BUSINESS OVERVIEW
FIGURE 25 BIOMX: COMPANY SNAPSHOT (2020)
13.1.12 YSOPIA BIOSCIENCE
TABLE 171 YSOPIA BIOSCIENCE: BUSINESS OVERVIEW
13.1.13 KALEIDO BIOSCIENCES, INC.
TABLE 172 KALEIDO BIOSCIENCES, INC.: BUSINESS OVERVIEW
FIGURE 26 KALEIDO BIOSCIENCES, INC.: COMPANY SNAPSHOT (2020)
13.1.14 FLIGHTPATH BIOSCIENCES, INC.
TABLE 173 FLIGHTPATH BIOSCIENCES, INC.: BUSINESS OVERVIEW
13.1.15 FINCH THERAPEUTICS GROUP, INC.
TABLE 174 FINCH THERAPEUTICS GROUP, INC.: BUSINESS OVERVIEW
FIGURE 27 FINCH THERAPEUTICS GROUP, INC.: COMPANY SNAPSHOT (2020)
13.1.16 QUANTBIOME, INC. (DBA OMBRE)
TABLE 175 QUANTBIOME, INC.: BUSINESS OVERVIEW
13.1.17 VIOME LIFE SCIENCES, INC.
TABLE 176 VIOME LIFE SCIENCES, INC.: BUSINESS OVERVIEW
13.1.18 BIOHM HEALTH
TABLE 177 BIOHM HEALTH: BUSINESS OVERVIEW
13.2 OTHER COMPANIES
13.2.1 DAYTWO
TABLE 178 DAYTWO: COMPANY OVERVIEW
13.2.2 ATLAS BIOMED
TABLE 179 ATLAS BIOMED: COMPANY OVERVIEW
13.2.3 BIONE
TABLE 180 BIONE: COMPANY OVERVIEW
13.2.4 LUXIA SCIENTIFIC
TABLE 181 LUXIA SCIENTIFIC: COMPANY OVERVIEW
13.2.5 METABIOMICS
TABLE 182 METABIOMICS: COMPANY OVERVIEW
13.2.6 SUN GENOMICS
TABLE 183 SUN GENOMICS: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

14 APPENDIX (Page No. – 182)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS


    • 리포트 제목은 자동으로 입력됩니다.
    • *항목은 필수항목입니다.

    의뢰분류*

    성함*

    회사명*

    부서명

    이메일*

    전화번호

    저희 사이트를 알게 된 경로를 가르쳐 주세요.

    문의 내용*

     

    ※개인정보보호정책은여기에서 확인 가능합니다。

    Email 문의도 받고 있습니다.
    아래 주소이며 죄송하지만 "(at)"을 "@"로 바꾸어 보내주시길 부탁드립니다.
    mooneui(at)chosareport-korea.com